한글목차

세계 무세포 태아 DNA 검사 시장의 미래는 병원 및 클리닉 센터의 응용 분야에서 기회로 인해 유망합니다. 세계 무세포 태아 DNA 검사 시장은 2025-2031년 12.3%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 유전성 질환에 대한 인식이 높아지고 산부인과에서 안전하고 위험이 적은 산전 진단 기술에 대한 선호도가 증가하고 있기 때문입니다.

• Lucintel의 예측에 따르면, 염색체 이상 검출은 다양한 염색체 이상 검출에 널리 사용되기 때문에 유형별로는 예측 기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다.
• 지역별로는 북미가 헬스케어 시스템이 발달하고 무세포 DNA 검사와 관련된 다양한 질병의 빈도가 증가함에 따라 예측 기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다.

무세포 태아 DNA 검사 시장의 전략적 성장 기회

cfDNA 검사의 전략적 성장 기회는 기술 발전과 비침습적 산전 검사에 대한 수요 증가로 인해 발생합니다. 다음과 같은 기회를 활용하여 시장의 성장과 혁신을 지원할 수 있습니다.

• 신흥 시장에서의 cfDNA 검사 확대는 높은 성장 잠재력을 보여주고 있습니다. 이러한 시장은 인지도를 높이고 의료 인프라를 개선한 후 이러한 기술을 채택할 가능성이 높으며, 이는 해당 지역에서의 매출 성장으로 이어질 것입니다.
• 디지털 건강 플랫폼: 디지털 건강 플랫폼을 cfDNA 검사에 통합하여 환자 참여와 데이터 관리를 강화할 수 있습니다. 이러한 통합은 검사 프로세스를 간소화하고 결과에 대한 접근을 용이하게 함으로써 이 부문의 성장을 가속할 것입니다.
• 종합적인 cfDNA 검사 패널의 개발: 종합적인 cfDNA 검사 패널의 개발은 보다 광범위한 유전자 질환을 포괄함으로써 성장 기회를 창출할 수 있습니다. 이러한 광범위한 패널은 임산부에게 더 많은 정보를 제공하고 더 나은 의사결정을 지원할 수 있습니다.
• 비용 효율적인 솔루션 개발: 비용 효율적인 cfDNA 검사 솔루션의 혁신은 보다 광범위한 시장 진입 기회를 제공합니다. 높은 정확도를 유지하면서 검사 비용을 확실히 낮추면 채택률 향상과 시장 침투를 촉진할 수 있습니다.
• 개인화 및 표적화 검사의 중요성: 개인화 및 표적화된 cfDNA 검사는 시장 성장을 더욱 두드러지게 할 수 있습니다. 개별화된 위험 평가를 제공하기 위해 특정 환자의 필요에 따라 맞춤화된 검사는 이러한 검사를 더욱 적절하게 만들고 수요를 증가시킬 것으로 보입니다.

cfDNA 검사 시장의 전략적 성장 기회에는 신흥 시장 진출, 디지털 헬스 플랫폼과의 통합, 종합적인 검사 패널 개발, 비용 효율적인 솔루션 개발, 개인 맞춤형 검사 제공 등이 있습니다. 이러한 노력은 시장 확대와 혁신을 촉진하고 있습니다. 이러한 기회를 이해함으로써 기업은 제품 제공을 강화하고 전체 시장의 성장을 지원할 수 있습니다.

무세포 태아 DNA 검사 시장 성장 촉진요인 및 과제

무세포 태아 DNA 검사 시장은 다양한 촉진요인 및 과제에 따른 다양한 영향에 따라 발전합니다. 기술적 변화, 경제적 요인, 규제 요건은 이 시장에 가장 큰 영향을 미치는 요인입니다.

무세포 태아 DNA 검사 시장을 촉진하는 요인은 다음과 같습니다.

• 기술 향상: cfDNA 검사 기술의 발전은 정확성과 효율성을 높입니다. 차세대 시퀀싱은 고급 알고리즘과 함께 보다 신뢰할 수 있고 완벽한 산전 진단 솔루션을 촉진하는 최근의 진보를 나타내며, 이를 통해 성장을 가속할 것입니다.
• 비침습적 검사에 대한 수요 증가: 비침습적 산전 검사에 대한 수요 증가는 시장 성장에 크게 기여하고 있으며, cfDNA 검사는 침습적 시술에 대한 보다 안전한 대안을 제공함으로써 산전 진단의 안전성에 대한 수요 증가에 대응하고 있습니다.
• 인식 및 채택 증가: cfDNA 검사에 대한 인식과 수용도가 높아지면서 시장 성장에 기여하고 있으며, cfDNA 검사의 가치에 대한 의료 서비스 제공업체와 임산부의 인식이 높아지면서 시장 확대가 촉진되고 있습니다.
• 규제 지원 및 가이드라인: 양호한 규제 환경과 최신 가이드라인이 시장 성장을 가속하고 있습니다. 승인 절차에 대한 면밀한 규제와 가이드라인은 cfDNA 검사의 안전성과 유효성을 보장하고 채택을 촉진합니다.
• 응용 분야의 확대: 종합적인 유전자 패널, 맞춤의료 등 새로운 응용 분야로의 cfDNA 검사의 확대가 시장 성장의 원동력이 되고 있습니다. 응용 분야의 확대는 수요를 증가시키고 시장 잠재력을 높입니다.

무세포 태아 DNA 검사 시장의 과제는 다음과 같습니다.

• 높은 검사 비용: cfDNA 검사와 관련된 높은 비용은 보급에 큰 걸림돌이 되고 있습니다. 검사 품질을 유지하면서 비용을 최소화하는 것은 접근성 향상과 시장 성장을 위해 매우 중요합니다.
• 복잡한 규제 요건: 규제 준수 및 상환 관련 문제는 시장 역학에 영향을 미칠 수 있습니다. 컴플라이언스 및 상환 범위는 시장의 성공을 좌우하는 중요한 요소입니다.
• 기술과 정확도의 한계: cfDNA 검사에 의한 위양성, 위음성 등 정확도에 대한 기술적 한계는 신뢰성에 영향을 미칠 수 있습니다. 신뢰를 유지하고 시장 성장을 가속하기 위해서는 이러한 문제를 해결해야 합니다.

기술 발전, 비침습적 검사에 대한 수요, 환자 인식 증가, 유리한 규제 정책, 응용 분야 확대는 cfDNA 검사 시장의 성장을 뒷받침할 것으로 보입니다. 그러나 높은 검사 비용, 규제 문제, 기술적 한계 등의 과제는 시장을 효과적으로 운영하고 성장 기회를 포착하기 위해 모니터링하고 해결해야 할 과제입니다.

목차

제1장 주요 요약

제2장 세계의 무세포 태아 DNA 검사 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 무세포 태아 DNA 검사 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별
  • 이상 염색체수 감지
  • 성별 검사
  • 부계 유전성 질환 감지
  • 부자 감정
  • 기타
• 용도별
  • 병원
  • 클리닉 센터
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 세계의 무세포 태아 DNA 검사 시장
• 북미의 무세포 태아 DNA 검사 시장
• 유럽의 무세포 태아 DNA 검사 시장
• 아시아태평양의 무세포 태아 DNA 검사 시장
• 기타 지역의 무세포 태아 DNA 검사 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 무세포 태아 DNA 검사 시장 성장 기회, 유형별
  • 세계의 무세포 태아 DNA 검사 시장 성장 기회, 용도별
  • 세계의 무세포 태아 DNA 검사 시장 성장 기회, 지역별
• 세계의 무세포 태아 DNA 검사 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 무세포 태아 DNA 검사 시장 능력 확대
  • 세계 무세포 태아 DNA 검사 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• The Fetal Medicine Centre
• Apollo Path labs
• Ariosa Diagnostics
• Sequenom Laboratories
• Laboratory Corporation of America Holdings
• Personal Genome Diagnostics
• Premaitha Health
• Berry Genomics
• Roche Holdings
• Trovagene

영문목차

The future of the global cell free fetal DNA testing market looks promising with opportunities in the hospital and clinic center applications. The global cell free fetal DNA testing market is expected to grow with a CAGR of 12.3% from 2025 to 2031. The major drivers for this market are rising consciousness regarding genetic disorders and a growing preference for secure and minimally risky prenatal diagnostic techniques in obstetrics.

• Lucintel forecasts that, within the type category, abnormal chromosome number detection is expected to witness the highest growth over the forecast period due to its widespread use in detecting a variety of chromosomal disorders.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to existence of developed healthcare system and increasing frequency of various diseases linked to cell-free DNA testing among population of the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Cell Free Fetal DNA Testing Market

The cell-free fetal DNA testing market is in the midst of several emerging trends that shape its future. These trends signify advanced technology, market demands, and changing health practices.

• Emerging Trends in cfDNA Testing Market: Innovation and transformation are being driven into the cfDNA testing market through emerging trends. Advancing technology, increasing access, and evolving health practices are reshaping how prenatal testing is performed and incorporated into standard care.
• Increased Accuracy and Sensitivity: Advancements in cfDNA testing technology increase its accuracy and sensitivity, making the diagnosis of several genetic conditions possible. These improvements allow for earlier and more reliable results, both of which are crucial for better prenatal care and decision-making.
• Expanded Testing Panels: There is a growing trend toward expanding cfDNA testing panels to cover an increasing number of genetic conditions. This breadth provides expectant parents with more substantial information on fetal health to assist them in making informed decisions.
• Integration into Prenatal Care: There is increased integration of cfDNA testing into the routine management of pregnant women. This allows more expectant mothers to receive early and non-invasive screening as part of their conventional prenatal care.
• Cost Reduction Efforts: Efforts toward cost reduction in cfDNA testing are increasing its potential use for more people. Innovations in technology and economies of scale decrease the cost of testing, enhancing affordability and access.

The emerging trends in cfDNA testing-increasing accuracy, expanding test panels, integrating into prenatal care, reducing costs, and improving data analytics-are transforming the market. These developments will drive further advancements in technology, access, and overall quality in prenatal diagnostics.

Recent Developments in the Cell Free Fetal DNA Testing Market

The rapidly evolving developments in the cell-free fetal DNA testing market are improving technology, increasing access, and facilitating clinical integration. These developments drive the pace and trajectory of market growth.

• Introduction of Next-Generation Sequencing: NGS technologies are being applied and developed to increase the accuracy and efficiency of cfDNA testing. NGS technology allows for complete genetic analysis, thus enhancing the detection of possible abnormalities and increasing the overall diagnostic capability of cfDNA testing.
• Market access is expanding, increasing the availability of testing. New initiatives include partnerships with healthcare providers and the integration of cfDNA testing into public health programs, which are bound to expand access to a wider population.
• Regulatory Approvals and Guidelines: Recent regulatory approvals and updated guidelines continue to shape the market by setting standards for cfDNA testing. Such approvals ensure that new technologies and methods meet safety and efficiency requirements, thereby influencing market adoption.
• Improved Sensitivity of Testing: Increased test sensitivity enables the detection of more genetic conditions. The more sensitive a test is, the more precisely risks can be determined, and the earlier any potential problems can be recognized, leading to benefits that may improve patient outcomes.
• Focus on Personalized Medicine: The emphasis on personalized medicine is driving innovation in the cfDNA testing field. Tailoring tests to meet the needs of each patient and integrating personalized risk assessments have become trends that add relevance and impact to test results.

Innovation in the cfDNA testing market involves advancements in NGS, increased market access through regulatory approvals, and enhanced sensitivity. The innovative ideas surrounding personalized medicine are driving growth and innovation, making prenatal testing increasingly viable, accurate, and accessible.

Strategic Growth Opportunities for Cell Free Fetal DNA Testing Market

Strategic growth opportunities in cfDNA testing arise from advancements in technology and the growing demand for non-invasive prenatal testing. The following opportunities can be capitalized on to support market growth and innovation:

• Expanding cfDNA testing in emerging markets shows high growth potential; such markets, after gaining awareness and improving their healthcare infrastructure, are likely to adopt these technologies, leading to revenue growth in those regions.
• Digital Health Platforms: The integration of digital health platforms into cfDNA testing will enhance patient engagement and data management. Such integration simplifies the testing process, making access to results easier, thereby promoting growth in the segment.
• Comprehensive cfDNA Testing Panel Development: Developing comprehensive cfDNA testing panels creates growth opportunities by covering a broader range of genetic conditions. These extensive panels provide more information and better decision-making support for expectant parents.
• Cost-Effective Solution Development: Innovations in cost-effective cfDNA testing solutions present opportunities for broader market access. Ensuring lower testing costs while maintaining high accuracy may drive higher adoption rates and deeper market penetration.
• Focus on Personalized and Targeted Testing: Personalized and targeted cfDNA testing can further underscore market growth. Tests tailored to specific patient needs, to provide personalized risk assessments, will make these tests more relevant and in greater demand.

Strategic growth opportunities in the cfDNA testing market include expanding into emerging markets, integrating with digital health platforms, developing comprehensive testing panels, creating cost-effective solutions, and offering personalized testing. These initiatives are driving the expansion and innovation of the market. By understanding these opportunities, companies can enhance product offerings and support overall market growth.

Cell Free Fetal DNA Testing Market Driver and Challenges

The cell-free fetal DNA testing market develops in response to diverse influences from various drivers and challenges. Technological changes, economic factors, and regulatory requirements are the most significant influences on this market.

The factors driving the cell-free fetal DNA testing market include:

• Technological Improvement: Advancements in cfDNA testing technology increase accuracy and efficiency. Next-generation sequencing, along with advanced algorithms, represents recent advances that facilitate more reliable and complete prenatal diagnostic solutions, thereby driving growth.
• Growing Demand for Non-Invasive Testing: The increasing demand for non-invasive prenatal testing methods significantly contributes to market growth. CfDNA testing offers a safer alternative to invasive procedures, catering to the rising demand for safety in prenatal diagnostics.
• Increasing Awareness and Adoption: Growing awareness and acceptance of cfDNA testing contribute to market growth. Increased awareness among healthcare providers and expectant parents about the value of cfDNA testing will facilitate market expansion.
• Regulatory Support and Guidelines: Favorable regulatory environments and updated guidelines are aiding market growth. Well-framed regulations and guidelines for approval procedures ensure the safety and efficacy of cfDNA testing, encouraging its adoption.
• Expanding Application Areas: The expansion of cfDNA testing into new application areas, such as comprehensive genetic panels and personalized medicine, drives market growth. Greater application raises demand, enhancing market potential.

Challenges in the cell-free fetal DNA testing market include:

• High Testing Costs: The high costs associated with cfDNA testing are a major obstacle to widespread adoption. Minimizing costs while maintaining test quality is crucial for enhancing accessibility and market growth.
• Complex Regulatory Requirements: Challenges related to regulatory compliance and reimbursement can influence market dynamics. Compliance and reimbursement coverage are key determinants of market success.
• Limitations of Technology and Accuracy: Technological limitations regarding accuracy, such as false positives or false negatives from cfDNA testing, can affect its reliability. These issues must be addressed to maintain trust and facilitate market growth.

Technological advancements, demand for non-invasive testing, increasing patient awareness, favorable regulatory policies, and expanding applications will support growth in the cfDNA testing market. However, challenges such as high testing costs, regulatory issues, and technological limitations need to be monitored and addressed to navigate the market effectively and seize growth opportunities.

List of Cell Free Fetal DNA Testing Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies cell free fetal DNA testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cell free fetal DNA testing companies profiled in this report include-

• The Fetal Medicine Centre
• Apollo Path labs
• Ariosa Diagnostics
• Sequenom Laboratories
• Laboratory Corporation of America Holdings
• Personal Genome Diagnostics
• Premaitha Health
• Berry Genomics
• Roche Holdings
• Trovagene

Cell Free Fetal DNA Testing by Segment

The study includes a forecast for the global cell free fetal DNA testing market by type, application, and region.

Cell Free Fetal DNA Testing Market by Type [Analysis by Value from 2019 to 2031]:

• Abnormal Chromosome Number Detection
• Gender Testing
• Paternally Inherited Disorder Detection
• Paternity Testing
• Others

Cell Free Fetal DNA Testing Market by Application [Analysis by Value from 2019 to 2031]:

• Hospital
• Clinic Center
• Others

Cell Free Fetal DNA Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cell Free Fetal DNA Testing Market

Significant growth in technological advancements and increasing adoption have contributed to improvements in the cfDNA testing market globally. Non-invasive prenatal testing through cell-free fetal DNA provides early and accurate information related to fetal health, affecting market conditions in many countries.

• United States: cfDNA testing in the U.S. is gradually focusing on increasing accuracy, expanding screening options, and applying new technologies to improve the detection of uncommon genetic disorders. Regulatory support and growing healthcare awareness are boosting market growth.
• China: The cfDNA testing market in China is growing due to increasing investments in R&D. Recent developments include incorporating cfDNA tests into routine prenatal care and increasing availability within urban and rural regions. Collaborations with international firms are advancing technology and making testing more affordable.
• Germany: In Germany, the integration of cfDNA testing into broader prenatal screening programs is gaining momentum. The increased use of advanced algorithms aims to improve the accuracy of risk assessments, while efforts continue to ensure standardized procedures for conducting tests across healthcare facilities to guarantee consistency and reliability.
• India: cfDNA testing is rising in India, driven by increasing healthcare awareness and improved access to health facilities. Efforts are being made to make testing options more affordable, positioning cfDNA testing as a standard in prenatal care to meet the growing demand for early and accurate prenatal diagnostics.
• Japan: Advancements in cfDNA testing in Japan are primarily driven by new technologies that offer better accuracy and patient management. Emerging technologies and improved algorithms are enhancing test sensitivity. The country is also focused on educating healthcare professionals about effectively utilizing cfDNA testing in clinical practice.

Features of the Global Cell Free Fetal DNA Testing Market

Market Size Estimates: Cell free fetal DNA testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Cell free fetal DNA testing market size by type, application, and region in terms of value ($B).

Regional Analysis: Cell free fetal DNA testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the cell free fetal DNA testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cell free fetal DNA testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cell free fetal DNA testing market by type (abnormal chromosome number detection, gender testing, paternally inherited disorder detection, paternity testing, and others), application (hospital, clinic center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cell Free Fetal DNA Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Cell Free Fetal DNA Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Cell Free Fetal DNA Testing Market by Type
  • 3.3.1: Abnormal Chromosome Number Detection
  • 3.3.2: Gender Testing
  • 3.3.3: Paternally Inherited Disorder Detection
  • 3.3.4: Paternity Testing
  • 3.3.5: Others
• 3.4: Global Cell Free Fetal DNA Testing Market by Application
  • 3.4.1: Hospital
  • 3.4.2: Clinic Center
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Cell Free Fetal DNA Testing Market by Region
• 4.2: North American Cell Free Fetal DNA Testing Market
  • 4.2.1: North American Market by Type: Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity Testing, and Others
  • 4.2.2: North American Market by Application: Hospital, Clinic Center, and Others
• 4.3: European Cell Free Fetal DNA Testing Market
  • 4.3.1: European Market by Type: Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity Testing, and Others
  • 4.3.2: European Market by Application: Hospital, Clinic Center, and Others
• 4.4: APAC Cell Free Fetal DNA Testing Market
  • 4.4.1: APAC Market by Type: Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity Testing, and Others
  • 4.4.2: APAC Market by Application: Hospital, Clinic Center, and Others
• 4.5: ROW Cell Free Fetal DNA Testing Market
  • 4.5.1: ROW Market by Type: Abnormal Chromosome Number Detection, Gender Testing, Paternally Inherited Disorder Detection, Paternity Testing, and Others
  • 4.5.2: ROW Market by Application: Hospital, Clinic Center, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cell Free Fetal DNA Testing Market by Type
  • 6.1.2: Growth Opportunities for the Global Cell Free Fetal DNA Testing Market by Application
  • 6.1.3: Growth Opportunities for the Global Cell Free Fetal DNA Testing Market by Region
• 6.2: Emerging Trends in the Global Cell Free Fetal DNA Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cell Free Fetal DNA Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cell Free Fetal DNA Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: The Fetal Medicine Centre
• 7.2: Apollo Path labs
• 7.3: Ariosa Diagnostics
• 7.4: Sequenom Laboratories
• 7.5: Laboratory Corporation of America Holdings
• 7.6: Personal Genome Diagnostics
• 7.7: Premaitha Health
• 7.8: Berry Genomics
• 7.9: Roche Holdings
• 7.10: Trovagene